FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...
Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.
The medication is an injectable branded Ebglyss and will be available in ... Pfizer's Cibinqo, Sanofi and Regeneron's ...
The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...
GlobalData on MSN17d
Sanofi’s Phase III CSU treatment trial meets endpointsSanofi has reported that its Phase III LIBERTY-CUPID Study C of Dupixent (dupilumab) in patients with chronic spontaneous ...
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback